These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 21992405)

  • 1. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.
    Moon S; Jambert E; Childs M; von Schoen-Angerer T
    Global Health; 2011 Oct; 7():39. PubMed ID: 21992405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
    Plahte J
    Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New pricing models for generic medicines to ensure long-term sustainable competition in Europe.
    Francois C; Gawlik G; Mestre-Ferrandiz J; Pana A; Perelman J; Yfantopoulos J; Simoens S
    Front Pharmacol; 2023; 14():1200641. PubMed ID: 37876734
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential pricing for pharmaceuticals: reconciling access, R&D and patents.
    Danzon PM; Towse A
    Int J Health Care Finance Econ; 2003 Sep; 3(3):183-205. PubMed ID: 14625999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
    Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
    BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The availability, pricing and affordability of three essential asthma medicines in 52 low- and middle-income countries.
    Babar ZU; Lessing C; Mace C; Bissell K
    Pharmacoeconomics; 2013 Nov; 31(11):1063-82. PubMed ID: 24127259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.
    Ocran Mattila P; Ahmad R; Hasan SS; Babar ZU
    Front Public Health; 2021; 9():628744. PubMed ID: 33996712
    [No Abstract]   [Full Text] [Related]  

  • 8. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
    Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
    J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Availability, Pricing, and Affordability of Essential Diabetes Medicines in 17 Low-, Middle-, and High-Income Countries.
    Babar ZU; Ramzan S; El-Dahiyat F; Tachmazidis I; Adebisi A; Hasan SS
    Front Pharmacol; 2019; 10():1375. PubMed ID: 31824316
    [No Abstract]   [Full Text] [Related]  

  • 11. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
    Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
    Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk sharing methods in middle income countries].
    Inotai A; Kaló Z
    Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cautionary Notes on a Global Tiered Pricing Framework for Medicines.
    Williams OD; Ooms G; Hill PS
    Am J Public Health; 2015 Jul; 105(7):1290-3. PubMed ID: 25973806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of medicines pricing policies in sub-Saharan Africa: systematic review.
    Koduah A; Baatiema L; de Chavez AC; Danso-Appiah A; Kretchy IA; Agyepong IA; King N; Ensor T; Mirzoev T
    Syst Rev; 2022 Dec; 11(1):257. PubMed ID: 36457058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs).
    Babar ZU
    Res Social Adm Pharm; 2024 Jun; ():. PubMed ID: 38908991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Availability, pricing and affordability of essential medicines in Eastern Ethiopia: a comprehensive analysis using WHO/HAI methodology.
    Sisay M; Amare F; Hagos B; Edessa D
    J Pharm Policy Pract; 2021 Jul; 14(1):57. PubMed ID: 34225781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 20. Determinants of price setting decisions on anti-malarial drugs at retail shops in Cambodia.
    Patouillard E; Hanson K; Kleinschmidt I; Palafox B; Tougher S; Pok S; O'Connell K; Goodman C
    Malar J; 2015 May; 14():224. PubMed ID: 26024880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.